Corpus overview


Overview

MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus


SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Gastroenterological and Hepatic Manifestations of Patients with COVID-19 MESHD, Prevalence, Mortality by Country, and Intensive Care Admission Rate: Systematic Review and Meta-analysis.

    Authors: Mohammad Shehab; Fatima Alrashed; Sameera Shuaibi; Dhuha Alajmi; Alan Barkun

    doi:10.1101/2020.10.29.20207167 Date: 2020-11-03 Source: medRxiv

    Background & Aims Patient infected with the SARS-COV2 usually report fever MESHD and respiratory symptoms MESHD. However, multiple gastrointestinal ( GI MESHD) manifestations such as diarrhea MESHD and abdominal pain MESHD has been described. The aim of this study was to evaluate the prevalence of GI MESHD, liver function test (LFT) abnormalities, and mortality of COVID19 MESHD patients. Methods We performed a systematic review and meta-analysis of published studies that included cohort of patients infected with SARSCOV2 from December 1st, 2019 to July 1st, 2020. We collected data from the cohort of patients with COVID19 MESHD by conducting a literature search using PubMed, Embase, Scopus, and Cochrane according to the preferred reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms MESHD, LFTs abnormalities MESHD and performed subanalyses to investigate the relationship between gastrointestinal symptoms, geographic location, fatality, and ICU admission. Results The available data of 17,802 positive patients for SARS-COV2 from 120 studies were included in our analysis. The most frequent manifestations were diarrhea MESHD, nauseated elevated LFTs. The overall and GI fatality MESHD were 7.2% , and 1% respectively. Subgroup analysis showed non statistically significant associations between GI symptoms/LFTs abnormalities MESHD and ICU admissions (OR=3.41, 95%). The GI MESHD mortality rate was 0.58% in China and 3.5% in the United States. Conclusion Digestive symptoms and LFTs abnormalities MESHD are common in COVID-19 MESHD patients. Our subanalysis shows that the presence of gastrointestinal MESHD and liver manifestations does not appear to affect mortality, or ICU admission rate. However, the mortality rate was higher in the United States compared to China.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.